Vaso Corporation (VASO)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 70 | 76 | 80 | 81 | 87 | 89 | 80 | - |
| Operating profit | $m | 2 | 3 | ||||||
| Net profit | $m | 0 | 6 | 12 | 5 | 1 | 2 | 3 | - |
| EPS reported | $ | 0.01 | 0.02 | ||||||
| Operating cashflow per share | $ | 0.05 | -0.02 | ||||||
| Capex per share | $ | 0.01 | 0.01 | ||||||
| FCF per share | $ | 0.05 | -0.02 | ||||||
| Free cash flow | $m | 8 | 7 | ||||||
| Net debt | $m | -35 | -37 | ||||||
| Book value equity | $m | 29 | 29 | ||||||
| Book value per share | $ | 0.17 | 0.17 | ||||||
| Number of shares | m | 176 | 175 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 19.65 | 28.16 | ||||||
| P/B LTM | x | 1.04 | 1.05 | ||||||
| P/S LTM | x | 0.35 | 0.38 | ||||||
| P/FCF LTM | x | 3.68 | 4.46 | ||||||
| EV/EBITDA LTM | x | 5.88 | -5.87 | ||||||
| EV/Sales LTM | x | -0.03 | 0.17 | ||||||
| Earnings Yield LTM | % | +5.09% | +3.55% | ||||||
| FCF Yield | % | +27.15% | +22.44% | ||||||
| Quality | |||||||||
| ROE | % | +5.33% | +6.23% | ||||||
| ROIC | % | +3.32% | -3.97% | ||||||
| Operating margin | % | +1.96% | +1.84% | ||||||
| Gross margin | % | +61.36% | +61.68% | ||||||
| FCF/Sales | % | +9.37% | -4.21% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +64.81% | +200.00% | ||||||
| Sales Growth YoY | % | +2.68% | -7.55% | ||||||
| Net Income Growth YoY | % | +64.98% | +193.80% | ||||||
| FCF Growth | % | +356.67% | +277.46% | ||||||
| Operating Profit Growth | % | +513.33% | +963.51% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 4.61 | 3.85 | ||||||
| Net Debt/EBITDA | x | 78.58 | 30.82 | ||||||
| EBIT/Net interest | x | 69.92 | 65.44 | ||||||
| Net debt/market cap | % | +0.93% | +0.83% | ||||||
| Net debt/Equity | x | -1.18 | -1.25 | ||||||
| Gross debt/equity | x | 0.06 | 0.06 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Vaso Corporation is a diversified enterprise engaged in both the healthcare equipment and information technology industries, serving markets within the United States and globally. The company's operations are structured across three primary divisions: 1. IT (Information Technology): This segment is dedicated to providing specialized IT solutions for the healthcare sector, alongside managed network technology services. Its services encompass managed diagnostic imaging applications, network infrastructure management, network transport, and comprehensive cybersecurity solutions. 2. Professional Sales Service: This division primarily focuses on the distribution of capital medical equipment manufactured by General Electric Healthcare (GEHC) to mid-sized healthcare providers. Its offerings include GEHC diagnostic imaging hardware, associated service contracts, training programs, and financial services facilitated by both GEHC and external partners. 3. Equipment: This segment concentrates on the development, manufacturing, sales, and servicing of its own proprietary medical devices. Its product portfolio features the Biox series, which includes Holter monitors and ambulatory blood pressure recorders; the ARCS series software for analyzing, reporting, and communicating ECG and blood pressure data; MobiCare multi-parameter wireless vital-sign monitoring systems; and Enhanced External Counterpulsation (EECP) therapy systems, used for non-invasive, outpatient treatment of ischemic heart disease. Founded in 1987, the company was originally named Vasomedical, Inc. before officially rebranding as Vaso Corporation in November 2016. Vaso Corporation maintains its corporate headquarters in Plainview, New York.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Vaso Corporation is a diversified enterprise engaged in both the healthcare equipment and information technology industries, serving markets within the United States and globally. The company's operations are structured across three primary divisions: 1. IT (Information Technology): This segment is dedicated to providing specialized IT solutions for the healthcare sector, alongside managed network technology services. Its services encompass managed diagnostic imaging applications, network infrastructure management, network transport, and comprehensive cybersecurity solutions. 2. Professional Sales Service: This division primarily focuses on the distribution of capital medical equipment manufactured by General Electric Healthcare (GEHC) to mid-sized healthcare providers. Its offerings include GEHC diagnostic imaging hardware, associated service contracts, training programs, and financial services facilitated by both GEHC and external partners. 3. Equipment: This segment concentrates on the development, manufacturing, sales, and servicing of its own proprietary medical devices. Its product portfolio features the Biox series, which includes Holter monitors and ambulatory blood pressure recorders; the ARCS series software for analyzing, reporting, and communicating ECG and blood pressure data; MobiCare multi-parameter wireless vital-sign monitoring systems; and Enhanced External Counterpulsation (EECP) therapy systems, used for non-invasive, outpatient treatment of ischemic heart disease. Founded in 1987, the company was originally named Vasomedical, Inc. before officially rebranding as Vaso Corporation in November 2016. Vaso Corporation maintains its corporate headquarters in Plainview, New York.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free